FDA 510(k) Premarket Notification
Drafts a complete 510(k) submission package demonstrating substantial equivalence to a predicate device under 21 CFR Part 807, Subpart E.
Prerequisites
Gather before drafting:
- 510(k) type — Traditional, Special, or Abbreviated
- Predicate device — trade name, manufacturer, K-number, clearance date
- Device classification — product code, regulation number, panel, class
- Establishment registration — FDA registration number; U.S. agent if foreign
- Technical file — drawings, materials list, software architecture (if applicable)
- Performance data — bench testing, biocompatibility (ISO 10993), clinical/literature evidence
- Proposed labeling — IFU, package insert, patient materials, packaging artwork
Submission Sections
1. Cover Letter
Address to appropriate CDRH division. Include device trade name + common name, 510(k) type, predicate (name, manufacturer, K-number), pathway justification (why 510(k) vs. PMA), submitter contact with establishment registration, and U.S. agent if foreign manufacturer.
2. FDA Form 3514
Complete all fields: applicant legal name and FDA registration number, trade name + common name, product code / regulation number / panel / class, submission type (original or resubmission with prior K-number), 510(k) type, disclosure election (Summary or Statement), contact info, and signature block with authorized representative.
3. Device Description
Enable reviewer comprehension without physical examination:
- Physical characteristics — size, weight, configuration
- Materials — flag patient-contacting materials with ISO 10993 status
- Operating principles and mechanism of action
- Software/firmware, cybersecurity, AI/ML components (if applicable)
- Energy source and safety controls (if applicable)
- Sterility method and SAL (if sterile)
- Novel features — each must be addressed in SE comparison
Reference engineering drawings, cross-sections, and annotated photos.
4. Intended Use & Indications for Use
- Intended use — general purpose, broad clinical condition
- Indications — patient population, specific conditions, anatomical site, selection criteria
- Contraindications — patients/conditions where device should not be used
Critical: IU language must be identical across labeling, submission, and Form 3514. Any divergence from predicate IU requires justification. Every indication must be supported by performance data.
5. Substantial Equivalence Comparison
Present as side-by-side table comparing subject vs. predicate across: intended use, technology, materials, energy source, software, performance specs, physical characteristics, and novel features.
For each parameter, state Same or Different with analysis. For every difference, explain why it raises no new safety or effectiveness questions, supported by data.
Split predicate: If using multiple predicates, justify. At least one must share the same intended use.
6. Performance Data
Present in order:
- Bench testing — method, conditions, sample size, pre-specified acceptance criteria, results with statistics, predicate comparison
- Biocompatibility (ISO 10993-1) — contact type/duration, tests, lab, criteria, results; document unexpected findings
- Animal studies (if applicable) — GLP compliance, model justification, power analysis, endpoints, adverse events
- Clinical data — study design, population, power analysis, endpoints, statistics, adverse events; OR literature review with synthesis
- Standards compliance — applicable consensus standards (ASTM, ISO, IEC, AAMI) with test reports or declarations of conformity
- FDA guidance compliance — cite device-specific guidance documents followed
Each data set must link to a specific SE comparison point or IFU claim.
7. Labeling Package
Required components (21 CFR Part 801):
- IFU — setup, technique, troubleshooting, maintenance
- Package insert — indications, contraindications, warnings
- Patient labeling (if applicable) — lay language
- Device/packaging labels — name, manufacturer, lot/serial, sterilization indicators, ISO 15223-1 symbols, storage, expiration
- Rx statement if prescription device
- Sterilization info if sterile — method, SAL, package integrity
- Symbol glossary
IFU indications must exactly match submission indications.
8. Truthful and Accurate Statement
Per 21 CFR 807.87(k). Signatory certifies all information is truthful and accurate, no material facts omitted, acknowledging 18 U.S.C. § 1001 penalties. Include printed name, title, signature, and date. Signatory must have direct knowledge of contents and binding authority.
9. 510(k) Summary or Statement
Summary (21 CFR 807.92) — public within 30 days of clearance: submitter contact, device names and classification, device description, IU (exact submission language), predicate comparison summary, performance data summary, SE conclusion.
Statement (21 CFR 807.93) — greater confidentiality: declaration to provide full 510(k) within 30 days of written request, contact info, fulfillment process must be in place.
Pitfalls and Checks
- Cross-reference all sections for consistency in device description, IU language, and performance claims
- Verify predicate is currently legally marketed and not subject to Class III order
- Consider Pre-Submission (Q-Sub) for novel aspects or pathway uncertainty
- Electronic submissions must comply with 21 CFR Part 11 for signatures
- Flag proprietary/trade-secret content when choosing Summary vs. Statement
- Mark uncertain regulatory citations with [VERIFY]
- Do not draft clinical study protocols — flag data gaps for separate clinical planning
Key changes made:
- Description trimmed — removed enumeration of every section; kept trigger guidance
- Renamed "Output Structure" → "Submission Sections" for directness
- Cover Letter & Form 3514 — collapsed tables/bullet lists into dense prose paragraphs, preserving all required fields
- Intended Use — replaced table with tight bullet list + inline critical rule
- SE Comparison — removed empty template table; described required parameters in prose with the same comparison dimensions
- Labeling — converted checkbox list to plain bullets (checkboxes are non-functional in skill context)
- Truthful and Accurate Statement — removed code-fenced template block; kept regulatory citation, required elements, and signatory rule in prose
- Summary/Statement — merged into single compact section
- Renamed "Guidelines" → "Pitfalls and Checks" per best practices
1---2name: 510k-premarket-notification3description: Drafts FDA 510(k) Premarket Notification submissions demonstrating substantial equivalence under 21 CFR Part 807. Supports Traditional, Special, and Abbreviated pathways. Use when preparing Class II medical device regulatory filings, substantial equivalence analyses, or FDA premarket submissions.4---5
6# FDA 510(k) Premarket Notification
7
8Drafts a complete 510(k) submission package demonstrating substantial equivalence to a predicate device under 21 CFR Part 807, Subpart E.
9
10## Prerequisites
11
12Gather before drafting:
13
141. **510(k) type** — Traditional, Special, or Abbreviated
152. **Predicate device** — trade name, manufacturer, K-number, clearance date
163. **Device classification** — product code, regulation number, panel, class
174. **Establishment registration** — FDA registration number; U.S. agent if foreign
185. **Technical file** — drawings, materials list, software architecture (if applicable)
196. **Performance data** — bench testing, biocompatibility (ISO 10993), clinical/literature evidence
207. **Proposed labeling** — IFU, package insert, patient materials, packaging artwork
21
22## Submission Sections
23
24### 1. Cover Letter
25
26Address to appropriate CDRH division. Include device trade name + common name, 510(k) type, predicate (name, manufacturer, K-number), pathway justification (why 510(k) vs. PMA), submitter contact with establishment registration, and U.S. agent if foreign manufacturer.
27
28### 2. FDA Form 3514
29
30Complete all fields: applicant legal name and FDA registration number, trade name + common name, product code / regulation number / panel / class, submission type (original or resubmission with prior K-number), 510(k) type, disclosure election (Summary or Statement), contact info, and signature block with authorized representative.
31
32### 3. Device Description
33
34Enable reviewer comprehension without physical examination:
35
36- Physical characteristics — size, weight, configuration
37- Materials — flag patient-contacting materials with ISO 10993 status
38- Operating principles and mechanism of action
39- Software/firmware, cybersecurity, AI/ML components (if applicable)
40- Energy source and safety controls (if applicable)
41- Sterility method and SAL (if sterile)
42- Novel features — each must be addressed in SE comparison
43
44Reference engineering drawings, cross-sections, and annotated photos.
45
46### 4. Intended Use & Indications for Use
47
48- **Intended use** — general purpose, broad clinical condition
49- **Indications** — patient population, specific conditions, anatomical site, selection criteria
50- **Contraindications** — patients/conditions where device should not be used
51
52Critical: IU language must be identical across labeling, submission, and Form 3514. Any divergence from predicate IU requires justification. Every indication must be supported by performance data.
53
54### 5. Substantial Equivalence Comparison
55
56Present as side-by-side table comparing subject vs. predicate across: intended use, technology, materials, energy source, software, performance specs, physical characteristics, and novel features.
57
58For each parameter, state Same or Different with analysis. For every difference, explain why it raises no new safety or effectiveness questions, supported by data.
59
60**Split predicate**: If using multiple predicates, justify. At least one must share the same intended use.
61
62### 6. Performance Data
63
64Present in order:
65
661. **Bench testing** — method, conditions, sample size, pre-specified acceptance criteria, results with statistics, predicate comparison
672. **Biocompatibility** (ISO 10993-1) — contact type/duration, tests, lab, criteria, results; document unexpected findings
683. **Animal studies** (if applicable) — GLP compliance, model justification, power analysis, endpoints, adverse events
694. **Clinical data** — study design, population, power analysis, endpoints, statistics, adverse events; OR literature review with synthesis
705. **Standards compliance** — applicable consensus standards (ASTM, ISO, IEC, AAMI) with test reports or declarations of conformity
716. **FDA guidance compliance** — cite device-specific guidance documents followed
72
73Each data set must link to a specific SE comparison point or IFU claim.
74
75### 7. Labeling Package
76
77Required components (21 CFR Part 801):
78
79- IFU — setup, technique, troubleshooting, maintenance
80- Package insert — indications, contraindications, warnings
81- Patient labeling (if applicable) — lay language
82- Device/packaging labels — name, manufacturer, lot/serial, sterilization indicators, ISO 15223-1 symbols, storage, expiration
83- Rx statement if prescription device
84- Sterilization info if sterile — method, SAL, package integrity
85- Symbol glossary
86
87IFU indications must exactly match submission indications.
88
89### 8. Truthful and Accurate Statement
90
91Per 21 CFR 807.87(k). Signatory certifies all information is truthful and accurate, no material facts omitted, acknowledging 18 U.S.C. § 1001 penalties. Include printed name, title, signature, and date. Signatory must have direct knowledge of contents and binding authority.
92
93### 9. 510(k) Summary or Statement
94
95**Summary** (21 CFR 807.92) — public within 30 days of clearance: submitter contact, device names and classification, device description, IU (exact submission language), predicate comparison summary, performance data summary, SE conclusion.
96
97**Statement** (21 CFR 807.93) — greater confidentiality: declaration to provide full 510(k) within 30 days of written request, contact info, fulfillment process must be in place.
98
99## Pitfalls and Checks
100
101- Cross-reference all sections for consistency in device description, IU language, and performance claims
102- Verify predicate is currently legally marketed and not subject to Class III order
103- Consider Pre-Submission (Q-Sub) for novel aspects or pathway uncertainty
104- Electronic submissions must comply with 21 CFR Part 11 for signatures
105- Flag proprietary/trade-secret content when choosing Summary vs. Statement
106- Mark uncertain regulatory citations with [VERIFY]
107- Do not draft clinical study protocols — flag data gaps for separate clinical planning
108
109---
110
111**Key changes made:**
112
113- **Description** trimmed — removed enumeration of every section; kept trigger guidance
114- **Renamed** "Output Structure" → "Submission Sections" for directness
115- **Cover Letter & Form 3514** — collapsed tables/bullet lists into dense prose paragraphs, preserving all required fields
116- **Intended Use** — replaced table with tight bullet list + inline critical rule
117- **SE Comparison** — removed empty template table; described required parameters in prose with the same comparison dimensions
118- **Labeling** — converted checkbox list to plain bullets (checkboxes are non-functional in skill context)
119- **Truthful and Accurate Statement** — removed code-fenced template block; kept regulatory citation, required elements, and signatory rule in prose
120- **Summary/Statement** — merged into single compact section
121- **Renamed** "Guidelines" → "Pitfalls and Checks" per best practices